Labs Farms Rovi Sa patent expiration
1. Risvan patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11241377 | LABS FARMS ROVI SA | Antipsychotic injectable depot composition |
May, 2031
(6 years from now) | |
| US11173110 | LABS FARMS ROVI SA | Risperidone or paliperidone implant formulation |
May, 2031
(6 years from now) | |
| US11007139 | LABS FARMS ROVI SA | Risperidone or paliperidone implant formulation |
May, 2031
(6 years from now) | |
| US10195138 | LABS FARMS ROVI SA | Methods for the preparation of injectable depot compositions |
May, 2031
(6 years from now) | |
| US10182982 | LABS FARMS ROVI SA | Antipsychotic injectable depot composition |
May, 2031
(6 years from now) | |
| US11759416 | LABS FARMS ROVI SA | Antipsychotic injectable depot composition |
May, 2031
(6 years from now) | |
| US11752094 | LABS FARMS ROVI SA | Antipsychotic injectable depot composition |
May, 2031
(6 years from now) | |
| US10085936 | LABS FARMS ROVI SA | Antipsychotic injectable depot composition |
May, 2031
(6 years from now) | |
| US10881605 | LABS FARMS ROVI SA | Methods for the preparation of injectable depot compositions |
May, 2031
(6 years from now) | |
| US10058504 | LABS FARMS ROVI SA | Methods for the preparation of injectable depot compositions |
May, 2031
(6 years from now) | |
| US10463607 | LABS FARMS ROVI SA | Antipsychotic Injectable Depot Composition |
May, 2031
(6 years from now) | |
| US11752093 | LABS FARMS ROVI SA | Antipsychotic injectable depot composition |
May, 2031
(6 years from now) | |
| US10335366 | LABS FARMS ROVI SA | Risperidone or paliperidone implant formulation |
May, 2031
(6 years from now) | |
| US11752092 | LABS FARMS ROVI SA | Methods for the preparation of injectable depot compositions |
May, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 29, 2027 |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 29 March, 2024
Treatment: Intramuscular administration of risperidone in extended release injectable suspension for treatment of schizophrenia in adults; Administration of risperidone in extended release injectable suspension ...
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
RISVAN family patents
